Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Development of a Core Outcome Set for Basal Cell Carcinoma (BCC), Including Low-Risk and Advanced Tumors. Journal of the American Academy of Dermatology Schlessinger, D. I., Reynolds, K. A., Dirr, M. A., Ibrahim, S. A., Yanes, A. F., Lazaroff, J. M., Godinez-Puig, V., Chen, B. R., Kurta, A. O., Cotseones, J. K., Chiren, S. G., Furlan, K. C., Iyengar, S., Behshad, R., DeHoratius, D. M., Denes, P., Drucker, A. M., Dzubow, L. M., Etzkorn, J. R., Harwood, C. A., Kim, J. Y., Lawrence, N., Lee, E. H., Lissner, G. S., Marghoob, A. A., Matin, R. N., Mattox, A. R., Mittal, B. B., Thomas, J. R., Zhou, X. A., Zloty, D., Schmitt, J., Kirkham, J. J., Armstrong, A. W., Basset-Seguin, N., Billingsley, E. M., Bordeaux, J. S., Brewer, J., Brown, M., Brown, M., Collins, S. A., Fargnoli, M. C., De Azevedo, S. J., Dummer, R., Eggermont, A., Goldman, G. D., Haedersdal, M., Hale, E., Hanlon, A., Harms, K. L., Huang, C. C., Hurst, E. A., In, G. K., Kelleners-Smeets, N., Kheterpal, M., Leshin, B., Mcdonald, M., Miller, S. J., Miller, A., Mostow, E. N., Trakatelli, M., Nehal, K. S., Ratner, D., Rogers, H., Sarin, K. Y., Soon, S. L., Stasko, T., Storrs, P. A., Tagliaferri, L., Vidimos, A. T., Wong, S. L., Yu, S. S., Zalaudek, I., Zeitouni, N. C., Zitelli, J. A., Poon, E., Sobanko, J. F., Cartee, T. V., Maher, I. A., Alam, M. 2022

Abstract

BACKGROUND: There is variation in the outcomes reported in clinical studies of basal cell carcinoma (BCC). This can prevent effective meta-analyses to answer important clinical questions.OBJECTIVE: To identify a recommended minimum set of core outcomes for BCC clinical trials.METHODS: Patient and professional Delphi process to cull a long-list, culminating in a consensus meeting. To be provisionally accepted, outcomes needed to be deemed 'important' (score: 7-9, of maximum of 9) by 70% of each stakeholder group.RESULTS: 235 candidate outcomes identified via a systematic literature review and survey of key stakeholders were reduced to 74 that were rated by 100 health care professionals and patients in two Delphi rounds. 27 outcomes were provisionally accepted. The final core set of 5 agreed-upon outcomes after the consensus meeting was: complete response; persistent or serious adverse events; recurrence-free survival; quality of life; and patient satisfaction, including with cosmetic outcome.LIMITATIONS: English-speaking patients and professionals rated outcomes extracted from English-language studies.CONCLUSIONS: A core outcome set (COS) for basal cell carcinoma has been developed. Use of relevant measures may improve the utility of clinical research and the quality of therapeutic guidance available to clinicians.

View details for DOI 10.1016/j.jaad.2022.04.059

View details for PubMedID 35551965